M&A Deal Summary |
|
|---|---|
| Date | 2019-01-29 |
| Target | Thermo Fisher Scientific - Anatomical Pathology Business |
| Sector | Medical Products |
| Buyer(s) | PHCHD |
| Sellers(s) | Thermo Fisher Scientific |
| Deal Type | Divestiture |
| Deal Value | 1.1B USD |
SEARCH BY
Try For Free 7-Day Free Trial
PHCHD is a healthcare company, that develops, manufactures sells, and services medical equipment and solutions across diabetes care, diagnostics, life sciences, and healthcare IT. PHCHD was founded in 2014 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 4 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 2 of 2 |
| State (Massachusetts) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2019) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-06-11 |
Bayer AG - Bayer Diabetes-Care Unit
Leverkusen, Germany
|
Buy | $1.1B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-09-05 |
MM France
Brignais, France MM France is a distributor of materials, equipment, and consumables for anatomo cyto pathology laboratories. MM France was formed in 1987 and is based in Brignais, France. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1956 |
| Sector | Test/Measurement Equipment |
| Employees | 122,000 |
| Revenue | 42.9B USD (2023) |
Thermo Scientific is a provider of analytical instruments, laboratory equipment, software, services, consumables and reagents for better workflow solutions spanning sample preparation, sample analysis, and data interpretation. Thermo Fisher Scientific was founded in 1956 and is based in Waltham, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 8 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 7 of 7 |
| State (Massachusetts) | 2 of 2 |
| Country (United States) | 6 of 6 |
| Year (2019) | 1 of 1 |
| Size (of disclosed) | 1 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-03-16 |
IntegenX
Pleasanton, New Jersey, United States IntegenX, Inc. is a developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics and biodefense applications. IntegenX, Inc. was established in 2003 and is based in Pleasanton, New Jersey. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-03-24 |
Brammer Bio
Cambridge, Massachusetts, United States Brammer Biopharmaceuticals LLC was founded early in 2015 to create a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO) to enable large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. With the in-depth biologics manufacturing knowledge and expertise of founders Mark Bamforth (CEO) and Steven Kasok (CFO), previously cofounders of Gallus Biopharmaceuticals, now as Brammer Bio, the company is positioned to accelerate the development of these important emerging technologies. |
Buy | $1.7B |
